Activation of adrenergic receptor β2 promotes tumor progression and epithelial mesenchymal transition in tongue squamous cell carcinoma

Abstract

Tongue squamous cell carcinoma (TSCC) is more aggressive than other cancers in the head and neck region because of its potential for metastasis. Recently, β2-adrenergic receptor (β2-AR) has been reported to be a potential promoter in various types of solid cancer. However, the role of β2-AR and its effect on TSCC is not well documented. Histological staining, western blot analysis, migration and invasion assay were used. In this study, the expression of β2-AR was increased in TSCC tissue compared with adjacent non-cancerous epithelium. Further analysis demonstrated that increased expression of β2-AR was correlated with differentiation, lymph node metastasis and reduced overall survival rate in patients with TSCC. In vitro studies confirmed that activation of β2-AR can promote epithelial mesenchymal transition in TSCC by initiating an interleukin-6/Stat3/Snail1 pathway. These results suggest that β2-AR has an oncogenic role in TSCC and may be a potential therapeutic target in TSCC.

Introduction

Tongue squamous cell carcinoma (TSCC) is the most common malignancy in the oral cavity. TSCC is more aggressive than other cancers of the oral cavity because of the propensity for rapid local invasion and spread. Unfortunately, the mortality rate of TSCC has not improved significantly and the 5-year survival rate has remained at <50% in the past 30 years despite increasing advances in therapeutic modalities. The major cause of TSCC-associated mortalities is local/regional relapse and metastasis. Previous studies demonstrated that epithelial mesenchymal transition (EMT) has a pivotal role in cancer invasion and metastasis (1,2). EMT is characterized by loss of cell polarity and adhesion, enhancement of cell motility and acquisition of a mesenchymal phenotype. It has been confirmed that reduced E-cadherin expression is a hallmark of EMT. The loss of E-cadherin has been linked with enhanced cell invasion and metastasis in oral SCC (3–5). Our previous studies demonstrated that E-cadherin expression was decreased in the budding tumor cells located ahead of invasive tumor front in TSCC, and expression was positively correlated with lymph node metastasis (6). Further studies confirmed that Snail2, histone-lysine N-methyltransferase EZH2 and microRNA-138 (7–9) regulate E-cadherin expression at the transcriptional and post-transcriptional levels. However, the molecular mechanisms underlining EMT process are still not fully understood in TSCC.

β2-adrenergic receptor (β2-AR) is a seven transmembrane receptor (also known as G protein-coupled receptor) required for the physiological response to adrenaline and noradrenaline. Notably, several studies indicated that the β2-AR pathway has an important role in solid cancer initiation and progression, including in breast cancer, malignant melanoma, prostate cancer and gastric cancer (10–13). More recent studies demonstrated that activation of β2-AR signaling was involved in EMT, and contributed to invasion and metastasis in colorectal adenocarcinoma and gastric cancer (14–16). However, the expression of β2-AR and its effect on TSCC progression have not well been documented. In this study, deregulation of β2-AR in TSCC was examined to investigate its roles in EMT and TSCC progression.

Materials and methods

Reagents and antibodies

Anti-β2-AR (cat. no. ab182136) was purchased from Abcam (Cambridge, UK), anti-interleukin-6 (IL-6; cat. no. 12153), anti-E-cadherin (cat. no. 9101s), anti-vimentin (cat. no. 9102s), anti-Snail (cat. no. 3879), anti-phospho-signal transducer and activator of transcription 3 (Stat3; cat. no. 12640) and anti-GAPDH (cat. no. 2118s) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Human IL-6 antibody (cat. no. AF-206-NA) were purchased from R&D Systems, Inc. (Minneapolis, MN, USA). Non-selective β-AR blocker, propranolol hydrochloride (cat. no. 318-98-9), non-specific β-AR agonist, isoproterenol hydrochloride (cat. no. 51-30-9), the β1-AR antagonist, metoprolol tartrate (cat. no. 56392-17-7) and the β2-AR antagonist ICI-118,551 hydrochloride (cat. no. 72795-19-8), were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). Anti-rabbit IgG, HRP-linked secondary antibody (cat. no. 7074s) was purchased from Cell Signaling Technology.

Patients and tissue samples

All tissue samples were collected between January 2007 and December 2009, obtained from the First Affiliated Hospital, Sun Yat-Sen University (Guangzhou, China). Patients with TSCC (n=75) were enrolled in this study. Adjacent non-cancerous tissue samples (n=20) and TSCC specimens (n=75) were used for immunohistochemical assessment. All tissue samples used in this study were used following the guidelines set by the Institution Review Board of Sun Yat-Sen University. All patients received radical surgery and none received any form of adjuvant therapy prior to surgery. The tumor extent was classified based on the TNM system by Union for International Cancer Control, and the tumor grade was classified following the World Health Organization classification of histological differentiation (6). Survival was calculated according to the date of surgery and the date of the last follow-up (or death). Informed consent was signed by all patients for the use of their tissue and clinical data in clinical analysis and research studies prior to treatment.

Immunohistochemistry and staining evaluation

Immunohistochemical staining was performed according to standard protocols (7). Samples were fixed in 4% paraformaldehyde for 24 h at room temperature and embedded in paraffin. Briefly, 4 µm thick tissue sections were dewaxed and hydrated routinely. Following antigen retrieval, tissue sections were incubated with primary antibodies at 4°C overnight. Samples were washed for five times with phosphate-buffered saline, then incubated with secondary antibody (1:200) at room temperature for 30 min. Tissues were treated with 3,3′-diaminobenzidine (1:200) for 1 min at room temperature and counterstained with hematoxylin for 10 sec at room temperature. After dehydration, slides were observed and analyzed using an Axioskop 40 (Carl Zeiss AG, Oberkochen, Germany) microscope. Five fields were randomly selected for each specimen under a light microscope at a magnification of ×400, and three experienced observers analyzed the images. The scoring criteria were according to a standard protocol described previously (7). A final score >4 was classified as high β2-AR expression and a score ≤4 was classified as low β2-AR expression.

Cell cultures and treatments

Cal27 and SCC15 TSCC cell lines were obtained from American Type Culture Collection (Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle's medium-F12 (Gibco: Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA), 1% penicillin and streptomycin. All cells were incubated at 37°C in a humidified atmosphere containing 5% CO₂ with the culture media changed every 2 days. Cultured cells were treated at 70 to 90% confluence and were serum-starved for 8 h before treatment. Briefly, cells were treated for 48 h according the groups as follows: i) Culture medium (control); ii) 1 µM propranolol (Prop); iii) 1 µM propranolol + 1 µM isoproterenol (Prop + ISO); iv) 1 µM metoprolol + 1 µM isoproterenol (Meto + ISO); v) 1 µM ICI-118,551 + 1 µM isoproterenol (ICI + ISO); and vi) 1 µM ISO. Propranolol, metoprolol and ICI-118,551 were added in the culture media 30 min before adding ISO.

IL-6/Stat3 signaling analysis

Cancer cells were cultured with medium containing 500 ng/ml IL-6 antibody (R&D Systems, Inc.) to neutralize and block IL-6 signaling in TSCC cells.

Immunofluorescence and laser scanning confocal microscopy

Samples were blocked with goat serum (Boster Biological Technology, Wuhan, China) and incubated with the primary antibody [E-cadherin (1:250), vimentin (1:250)] diluted in 5% bovine serum albumin (BSA; Boster Biological Technology) at 4°C overnight. Secondary antibody conjugated to fluorescein isothiocyanate was used to bind to the primary antibody (1:200) diluted in PBS at 37°C for 30 min. Nuclei were stained with DAPI (1:250; Sigma-Aldrich; Merck KGaA) diluted in PBS at 37°C for 5 min. Samples were placed on glass coverslip. Cells were observed using a confocal laser scanning microscope (Zeiss LSM 510 Meta; Carl Zeiss AG).

Migration and invasion assay

Cell migration assay was evaluated by using wound healing and Transwell membrane chambers (8 µm pore size; Corning Inc., New York, NY, USA). The wound healing assay was performed as previously described (16). Briefly, the cells were seeded in 12-well plates and treated with ISO at 90% confluence and normal culture medium was added to the control cells. For Transwell membrane chambers, cells were seeded into the upper chambers and cultured with or without ISO for 36 h. For invasion assay, top chambers coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) at a concentration of 1.37 mg/ml. Upper chambers were fixed in 4% paraformaldehyde at room temperature for 30 min, stained using 0.1% crystal violet at room temperature for 5 min, then counted using a Axioskop 40 (Carl Zeiss AG) microscope.

Western blot analysis

Cells were lysed on ice in 120 µl radioimmunoprecipitation lysis buffer containing phosphatase inhibitors (Sigma-Aldrich; Merck KGaA) for 30 min. Total proteins (30 µg; determined by bicinchoninic acid assay) were loaded and separated by 10% SDS-PAGE, and then transferred into nitro-cellulose membrane (EMD Millipore, Billerica, MA, USA). Membranes were blocked in 5% evaporated skimmed milk at room temperature for 1 h and then incubated with primary antibody at 4°C overnight. Primary antibodies (1:1,000) were diluted in 5% evaporated skimmed milk at 4°C overnight. Then incubated the membrane with horseradish peroxidase-conjugated secondary antibody (1:2,000; diluted in 5% evaporated skimmed milk at room temperature for 1 h; Cell Signaling Technology, Inc.) and observed using chemiluminescence (EMD Millipore).

Statistical analysis

Data was presented as mean ± SD. All experiments were performed at least three times and all statistical analyses were performed using SPSS 13.0 software for Windows (SPSS, Inc., Chicago, IL, USA). The association between β2-AR expression and the clinical pathological parameters was determined by χ² test. The survival analysis was performed by the Kaplan-Meier method. Student's t-test was used for statistical analysis. P<0.05 was considered to indicate a statistically significant difference. A Cox regression was used to analyze the association between the survival time and the clinicopathological variables.

Results

Expression of β2-AR in TSCC samples

The expression of p-β2-AR was detected by immunohistochemistry in 75 cases with TSCC. The β2-AR was detected in at low levels in adjacent non-cancerous epithelium (ANCE). In primary tumor samples, predominant cytoplasm and membrane staining of β2-AR was detected in cancer cells (Fig. 1A). The semi-quantitative analysis revealed that β2-AR was overexpressed in TSCC compared with ANCE (Fig. 1B). Enhanced expression of β2-AR was also observed in TSCC with lymph node metastasis compared with TSCC samples without lymph node metastasis (Fig. 1C). β2-AR expression was increased SCC tissue with poor differentiation compared with well differentiated TSCC tissue (Fig. 1D). Among 75 cases examined in the study, 36 (48%) cases exhibited high β2-AR staining and 40 (52%) cases displayed low β2-AR expression.

Figure 1.

Expression of β2-AR in TSCC samples. (A) Expression of β2-AR in ANCE and TSCC samples (upper images scale bar, 50 µm; lower images scale bar, 20 µm). (B) Semi-quantitative analysis revealed that β2-AR is overexpressed in TSCC compared with ANCE. (C) Expression of β2-AR was enhanced in TSCC with lymph node metastasis when compared with TSCC samples without lymph node metastasis. (D) Expression of β2-AR was increased in TSCC tissue with poor differentiation than with well differentiation. Scale bar, 50 µm. Error bars represent the standard deviation; ^**P<0.01. β2-AR, β2-adrenergic receptor; TSCC, tongue squamous cell carcinoma; ANCE, adjacent non-cancerous epithelium.

Association of β2-AR with clinicopathological features in TSCC

Associations were tested between β2-AR expression and clinical and pathological features in this TSCC cohort (Table I). χ² analysis demonstrated that β2-AR expression was associated with tumor differentiation (P=0.004) and N stage (P=0.013). There were no associations between β2-AR expression and age, gender, T stage and clinical stage.

Table I.

Association between β2-AR expression and clinicopathological features in patients with tongue squamous cell carcinoma.

Clinicopathologic feature	No. of cases	β2-AR expression		P-value
		High (%)	Low (%)
Gender
Male	38	19	19	0.725
Female	37	17	20
Age (years)
≥55	40	21	19	0.404
<55	35	15	20
Differentiation
Well	40	13	27	0.004
Moderate+poor	35	23	12
T stage
T1–2	68	34	34	0.280
T3–4	7	2	5
N stage
N−	52	20	32	0.013
N+	23	16	7
Clinical stage
I–II	48	20	28	0.143
III–IV	27	16	11

β2-AR, β2-adrenergic receptor.

Prognostic value of β2-AR for patients with TSCC

Kaplan-Meier analysis demonstrated a statistically significant difference in 5-year survival rate between patients with high β2-AR expression and low β2-AR expression (P=0.003; Fig. 2). As demonstrated in Table II, univariate analysis indicated that tumor size, grade, pathological T stage, lymph node metastasis, clinical stage, and β2-AR were all significant prognostic factors for survival of patients with TSCC. Multivariate analysis showed that lymph node metastasis, clinical stage, and β2-AR were all independent prognostic factors for patient survival.

Figure 2.

Kaplan-Meier analysis. Kaplan-Meier analysis demonstrate a statistically significant difference in 5-year survival rate between high β2-AR expression group and low β2-AR expression group. P-value was determined using the log-rank test. β2-AR, β2-adrenergic receptor.

Table II.

Cox proportional analysis of variables affecting survival in patients with tongue squamous cell carcinoma.

– Variable	Comparison	Univariate analysis		Multivariate analysis
		HR (95% CI)	P-value	HR (95% CI)	P-value
Gender	Male vs. female	1.059 (0.475–2.359)	0.889
Age (years)	≥55 vs. <55	0.996 (0.442–2.246)	0.992
Differentiation	Well vs. moderate or poor	0.712 (0.319–1.588)	0.406
pT stage	T1–2 vs. T3–4	2.392 (0.893–6.409)	0.083
pN stage	N0 vs. N+	3.070 (1.372–6.871)	0.006	0.878 (0.168–4.596)	0.877
pTNM stage	I–II vs. III–IV	3.039 (1.346–6.860)	0.007	2.823 (0.582–13.696)	0.198
β2-AR expression	High vs. low	3.220 (1.396–7.428)	0.006	2.780 (1.090–7.086)	0.032

pTNM stage, pathological tumor node metastasis stage; β2-AR, β2-adrenergic receptor; HR, hazard ratio; CI, confidence interval.

Effect of activation of β2-AR on EMT in TSCC cells

TSCC cell lines Cal27 and SCC15 were treated with ISO (β-AR agonist) to activate β2-AR signaling. The cell morphology was dramatically changed from an epithelial phenotype to mesenchymal phenotype with decreased E-cadherin expression and increased vimentin expression (Fig. 3A and B). A wound healing assay indicated that these changes were accompanied by enhanced cell motility (Fig. 4A and B). Similar results were also observed in Transwell assay coated with or without Matrigel (Fig. 5A and B). Western blot analyses further confirmed that E-cadherin expression was downregulated and vimentin expression was upregulated by treatment with ISO (Fig. 5C and D). By contrast, western blot analysis indicated that ISO-mediated activation of β2-AR (p-β2-AR), increased expression of vimentin and Snail1, and reduced E-cadherin expression were inhibited by co-treatment with ICI-118,551, but not metoprolol (Fig. 6A and B). The expression of IL-6, Stat3, p-Stat3 and Snail1 were also examined in TSCC cells treated by ISO with or without ICI-118,551. Activation of β2-AR promoted the expression of IL-6, p-Stat3 and Snail1, while blockade of β2-AR signaling with ICI-118,551 inhibited β2-AR-mediated activation of IL-6/Stat3/Snail pathway (Fig. 7A). When cells were treated with anti-IL-6 monoclonal antibody (mAb), ISO-induced EMT was partially reversed by blocking IL-6/Stat3/Snail pathway (Fig. 7B) (24).

Figure 3.

Light microscope and laser scanning confocal microscopy observations indicate that ISO induced epithelial mesenchymal transition morphological alterations in Cal27 and SCC15 cell lines. (A) Cal27 and (B) SCC15 cell lines, cell morphology was dramatically changed from epithelial phenotype to mesenchymal phenotype. E-cadherin expression was decreased and vimentin expression was increased. ISO, isoproterenol.

Figure 4.

Wound healing assay. (A) In Cal27 cell lines and (B) SCC15 cell lines, the ability of wound healing was increased in ISO-treated groups compared with controls and the ability was similar in Prop + ISO group and control groups. Error bars represent the standard deviation; ^*P<0.05. ISO, isoproterenol; Prop, propranolol.

Figure 5.

Prop attenuates ISO-stimulated Cal27 and SCC15 cell migration and invasion by inhibiting ISO-induced epithelial mesenchymal transition. Representative, (A) ISO increased cells migration and invasion and attenuated by Prop in Cal27 and (B) SCC15. Western blot analysis indicated that, (C) in Cal27 and (D) SCC15 cells, E-cadherin expression was downregulated and vimentin expression was upregulated in ISO exposed groups than controls. Error bars represent the standard deviation; ^*P<0.05. Prop, propranolol; ISO, isoproterenol.

Figure 6.

Western blot analysis indicates that ISO induced epithelial mesenchymal transition through mediating activation of β2-AR. (A) In Cal27 and (B) SCC15 cell lines, p-β2-AR, vimentin and Snail1 were increased in ISO-treated groups, while E-cadherin expression were decreased. Following treatment with ICI-118,551 but not Meto, ISO induced the expression of vimentin and Snail1, and E-cadherin was attenuated. p-, phospho; β2-AR, β2-adrenergic receptor Meto, metoprolol; ISO, isoproterenol.

Figure 7.

Activation of β2-AR promoted epithelial mesenchymal transition in Cal27 and SCC15 cells through initiating IL-6/Stat3/Snail1 pathway. (A) Expression of IL-6, Stat3, p-Stat3 and Snail1 in Cal27 and SCC15 cells treated by ISO with or without ICI-118,551. (B) Expression of IL-6, Stat3, p-Stat3 and Snail1 in the presence of IL-6 mAb, ISO and ICI-118,551. ISO, isoproterenol; β2-AR, β2-adrenergic receptor; IL-6, interleukin-6; mAb, monoclonal antibody; Stat3, signal transducer and activator of transcription 3; p-, phospho.

Discussion

Accumulating data demonstrate that EMT has an important role in malignant cancer progression (17,18). Cancer cells can acquire the ability to migrate and invade during EMT, which is orchestrated by a complex molecular network. Recently, stress has been reported to be correlated with cancer growth, drug resistance, recurrence, progression and poor prognosis of patients (12). Stress activates the sympathetic nervous system and results in increased production of catecholamines, such as norepinephrine and epinephrine (12). The activation of β2-AR signaling was indicated to be responsible for stress-mediated cancer progression (19,20). The oncogenic role of β2-AR has been suggested in several cancers type, including oral cancer (21,22). However, the deregulation of β2-AR in TSCC and its role in invasion and metastasis of TSCC has not been fully investigated.

In the present study, the expression of β2-AR was examined in TSCC tissue samples, and it was confirmed that β2-AR expression was enhanced in TSCC tissue compared with non-cancerous adjacent epithelium. This observation indicates that deregulation of β2-AR signaling may contribute to TSCC tumorigenesis. Similar results were previously observed in other studies (22). Further analysis demonstrated that increased expression of β2-AR was positively associated with lymph node metastasis, clinical stage and reduced overall survival. Furthermore, overexpression of β2-AR was an independent poor prognostic factor in patients with TSCC. These findings indicated that activation of β2-AR signaling has a critical role in the invasion and metastasis cascade in TSCC. Notably, Bravo-Calderón et al (21) reported that strong expression of β2-AR was a favorable prognostic factor for patients with OSCC.

To confirm the observations above and explore the functional relevance of β2-AR in invasion and metastasis of TSCC, TSCC cells were treated with ISO (β-AR agonist) and/or propranolol (non-selective β-AR antagonist) to activate or block β-AR signaling pathway; a switch of TSCC cells from epithelial to mesenchymal phenotype was observed in cancer cells, which suggested that EMT was induced when cancer cells were treated with ISO. The switch was also accompanied by decreased expression of E-cadherin, increased expression of vimentin and enhanced cell migration and invasion. These changes were also abolished by treatment with propranolol. To further confirm that activation of β2-AR was responsible for the ISO-induced EMT, metoprolol (selective β1-AR antagonist) and ICI-118,551 (selective β2-AR antagonist) were used to inhibit β1-AR and β2-AR signaling, respectively. Inhibition of β2-AR reversed ISO-induced EMT. These findings confirmed that activation of β2-AR induced EMT to promote migration and invasion in TSCC cells. Similar results were also reported by Lu et al (15) and Shan et al (16). However, the molecular mechanisms of β2-AR-mediated EMT in TSCC are not clear. Bernabé et al (23) reported that β-AR agonists, such as norepinephine, and ISO stimulation both increase IL-6 secretion in human oral SCC cells lines. As previously reported (24–26), the IL-6/Stat3 pathway has an important role in EMT. To further clarify the potential mechanism of β2-AR induced EMT, IL-6/Stat3/Snail1 pathways were investigated in our study. In the current study, increased production of IL-6 was observed in Cal27 and SCC15 cells following ISO stimulation, which was also associated with activation of Stat3 and increased Snail1 expression to initiate EMT. Notably, these molecular changes can be blocked by treatment with IL-6 mAb. These results suggested that activation of IL-6/Stat3/Snail pathway is involved in β2-AR mediated EMT in oral SCC.

In conclusion, the results of the present study demonstrated that deregulation of β2-AR signaling may be involved in TSCC progression. One of its major roles is promoting EMT to enhance cancer cell migration and invasion in TSCC progression. Furthermore, β2-AR-mediated EMT was regulated in TSCC, at least in part, through activation of an IL-6/Stat3/Snail pathway. Further studies are necessary to investigate the cross-talk between β2-AR and IL-6 signaling.